315 related articles for article (PubMed ID: 31082852)
1. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of Systemic Melanoma Treatments.
Mukunda N; Vallabhaneni S; Lefebvre B; Fradley MG
Curr Treat Options Oncol; 2022 Feb; 23(2):240-253. PubMed ID: 35192138
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.
Deutsch A; Leboeuf NR; Lacouture ME; McLellan BN
Am Soc Clin Oncol Educ Book; 2020 May; 40():485-500. PubMed ID: 32421446
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Toxicities in Pediatric Cancer Survivors.
Ryan TD; Nagarajan R; Godown J
Cardiol Clin; 2019 Nov; 37(4):533-544. PubMed ID: 31587793
[TBL] [Abstract][Full Text] [Related]
5. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
7. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.
Ryan TD; Nagarajan R; Godown J
Curr Treat Options Oncol; 2019 May; 20(7):56. PubMed ID: 31129800
[TBL] [Abstract][Full Text] [Related]
8. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
[TBL] [Abstract][Full Text] [Related]
9. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines.
Alexandre J; Cautela J; Ederhy S; Damaj GL; Salem JE; Barlesi F; Farnault L; Charbonnier A; Mirabel M; Champiat S; Cohen-Solal A; Cohen A; Dolladille C; Thuny F
J Am Heart Assoc; 2020 Sep; 9(18):e018403. PubMed ID: 32893704
[TBL] [Abstract][Full Text] [Related]
11. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
Gutierrez C; Rajendram P; Pastores SM
Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
13. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.
Zheng PP; Li J; Kros JM
Med Res Rev; 2018 Jan; 38(1):325-376. PubMed ID: 28862319
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
Yeh ETH; Ewer MS; Moslehi J; Dlugosz-Danecka M; Banchs J; Chang HM; Minotti G
Semin Oncol; 2019 Dec; 46(6):397-402. PubMed ID: 31753424
[TBL] [Abstract][Full Text] [Related]
15. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.
Berardi R; Caramanti M; Savini A; Chiorrini S; Pierantoni C; Onofri A; Ballatore Z; De Lisa M; Mazzanti P; Cascinu S
Crit Rev Oncol Hematol; 2013 Oct; 88(1):75-86. PubMed ID: 23522920
[TBL] [Abstract][Full Text] [Related]
16. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
17. Mathematical modeling of cardio-oncology: Modeling the systemic effects of cancer therapeutics on the cardiovascular system.
Casson CL; John SA; Ferrall-Fairbanks MC
Semin Cancer Biol; 2023 Dec; 97():30-41. PubMed ID: 37979714
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.
Ng CY; Chen CB; Wu MY; Wu J; Yang CH; Hui RC; Chang YC; Lu CW
J Immunol Res; 2018; 2018():5376476. PubMed ID: 29577050
[TBL] [Abstract][Full Text] [Related]
19. Interactions between cardiology and oncology drugs in precision cardio-oncology.
Kamaraju S; Mohan M; Zaharova S; Wallace B; McGraw J; Lokken J; Tierney J; Weil E; Fatunde O; Brown SA
Clin Sci (Lond); 2021 Jun; 135(11):1333-1351. PubMed ID: 34076246
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
